Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Operating Leases (2018 - 2025)

Achieve Life Sciences (ACHV) has disclosed Operating Leases for 8 consecutive years, with $5000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 92.42% to $5000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5000.0 through Dec 2025, down 92.42% year-over-year, with the annual reading at $5000.0 for FY2025, 92.42% down from the prior year.
  • Operating Leases for Q4 2025 was $5000.0 at Achieve Life Sciences, down from $21000.0 in the prior quarter.
  • The five-year high for Operating Leases was $69000.0 in Q4 2022, with the low at $4000.0 in Q4 2021.
  • Average Operating Leases over 5 years is $35500.0, with a median of $37500.0 recorded in 2023.
  • The sharpest move saw Operating Leases tumbled 94.81% in 2021, then soared 1625.0% in 2022.
  • Achieve Life Sciences' Operating Leases stood at $4000.0 in 2021, then soared by 1625.0% to $69000.0 in 2022, then plummeted by 91.3% to $6000.0 in 2023, then skyrocketed by 1000.0% to $66000.0 in 2024, then plummeted by 92.42% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for ACHV's Operating Leases are $5000.0 (Q4 2025), $21000.0 (Q3 2025), and $37000.0 (Q2 2025).